Atomoxetine or methylphenidate for children with ADHD
About this title
Read the official source — NCT00486083This study evaluated the safety and effectiveness of Atomoxetine Hydrochloride for people with ADHD.
Understand this study
What did researchers investigate?
This study evaluated the safety and effectiveness of Atomoxetine Hydrochloride for people with ADHD.
Who was this study for?
Listed age limits: 6 years to 16 years.
- Listed locations
- Shanghai and 2 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
- Recruitment status
- Completed
- Enrollment listed in the registry
- 330
- Sponsor
- Eli Lilly and Company
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- China, Mexico, South Korea
- Age range
- From 6 Years to 16 Years
- Official registry ID
- NCT00486083
- Official title
Show the full official title
A Randomized, Double-Blind Comparison, Safety and Efficacy Trial of Atomoxetine Hydrochloride and Methylphenidate Hydrochloride in Pediatric Outpatients With DSM-IV Attention-Deficit/Hyperactivity Disorder
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
Shanghai, China · Mexico City, Mexico · Seoul, South Korea
Interested in joining this study?
Questions about this study
What did researchers investigate?
This study evaluated the safety and effectiveness of Atomoxetine Hydrochloride for people with ADHD.
Who is behind this study?
The study sponsor is Eli Lilly and Company.
Did this study involve medication?
Yes. The study involved medication, including Atomoxetine Hydrochloride and Methylphenidate Hydrochloride.
Who was this study for?
Listed age limits: 6 years to 16 years.
